




CALL FOR EXPRESSIONS OF INTEREST
MAPS Pillar 2: Support for Nigerian pharmaceutical manufacturers towards WHO prequalification
| Call opens | Wednesday November, 4th 2026 |
|---|---|
| Information session | Tuesday, November 19, 11:00 WAT, online |
| Closing date | Tuesday November 17, 2026, 17:00 West Africa Time (WAT) |
| How to apply | Send the completed EOI form and five documents (section 8) |
1. About this call
The Manufacturing Advancements and Prequalification Support (MAPS) project is supported by the European Union through Global Gateway, in collaboration with the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) and the Nigeria Sovereign Investment Authority (NSIA/NHDIC). MAPS links local excipient manufacturing (Pillar 1) with support to manufacturers of finished medicines (Pillar 2).
Under Pillar 2, MAPS will select between three and five priority products made by Nigerian manufacturers and support them to reach, or come close to, the point of submitting a dossier for WHO prequalification. WHO prequalification opens the door to tenders run by international buyers such as the Global Fund and UNICEF, and to faster registration in other African countries.
Selection also gives weight to what each product will do for Nigeria: more local manufacturing of priority medicines, more skilled jobs, and a larger share of the ECOWAS and wider African market.
2. What selected manufacturers receive?
Selected manufacturers receive technical assistance from experienced WHO prequalification and good manufacturing practice (GMP) experts, funded by MAPS at no fee to the manufacturer. Support covers:
- a WHO prequalification readiness assessment of the site and the candidate product
- a gap assessment of the quality management system (QMS), GMP and data integrity
- help to plan and carry out corrective and preventive actions (CAPA)
- strengthening of standard operating procedures (SOPs)
- process validation and equipment qualification
- preparation of the product dossier in the Common Technical Document (CTD) format, Modules 1 to 5
- regulatory mentoring through to dossier submission
- links to regional registration routes and to public and pooled buyers
Duration of support: [3 months]. Indicative value of support per manufacturer: [to be covered by MAPS].
3. What manufacturers contribute?
Technical assistance can close gaps in systems, procedures, validation and documentation. It cannot pay for equipment or building works. Selected manufacturers are therefore expected to provide:
- investment to close any gaps in infrastructure found during the assessment, for example in air handling, water systems or power backup
- the cost of a bioequivalence study, where the product needs one
- a named WHO prequalification team with time set aside for the work, and staff for training sessions
- access to the site, records and staff for the assessment and mentoring team
As a rough guide, manufacturers typically fund the cost of infrastructure improvements and, where needed, bioequivalence studies. The amount of each manufacturer’s contribution will be agreed after the gap assessment, based on the gaps found, and confirmed by a board resolution. Manufacturers are not asked to commit an amount at the EOI stage.
4. Who can apply?
Pharmaceutical manufacturers registered in Nigeria, making finished medicines at a site in Nigeria, may apply. Firms of all sizes and in all states are encouraged to apply. To be eligible, a manufacturer must hold:
- company registration with the Corporate Affairs Commission (CAC)
- a current manufacturing premises licence from the Pharmacy Council of Nigeria (PCN)
- a current NAFDAC manufacturing facility licence covering the dosage form of the candidate product
- a current NAFDAC GMP certificate
- NAFDAC registration of the candidate product, or evidence that its application is at an advanced stage of NAFDAC evaluation
These five documents are the only pass/fail requirements at the EOI stage.
Other documents, such as tax clearance certificates, environmental and fire safety permits, superintendent and board pharmacist documents, and evidence that inspection CAPAs have been closed, are not needed with the EOI. Shortlisted manufacturers will provide them with the full application. Documents that are being renewed are accepted with proof of the renewal application, and any missing document can be supplied within ten working days of being requested.
5. Which products are eligible?
WHO only prequalifies products it has publicly invited manufacturers to submit. It publishes these invitations as lists for each disease area. A product that is not on a current WHO invitation cannot be prequalified, however good the factory is.
Annex 1 lists the products that are eligible for this call. They are taken from the current WHO invitations and grouped by disease area. A manufacturer may propose up to three candidate products. Products on PVAC’s priority list receive additional weight in scoring.
All dosage forms on the WHO invitations are welcome, including injectables, dispersible tablets, oral liquids and suppositories. Where a requirement does not apply to a dosage form (for example, a bioequivalence study for an injectable), it is not counted against the manufacturer.
6. How selection works?
Selection runs in four steps, so that manufacturers only prepare detailed documents once they have been shortlisted.
| Step | What happens |
| 1. Expression of interest (this call) | You send the short EOI form and the five documents in section 4. Applications are checked for eligibility and basic readiness. |
| 2. Full application | Shortlisted manufacturers submit the full application: site master file, quality documents, product information, three years of financial statements, market and jobs information, and a declaration of other support received. Applications are scored out of 100. To go forward, a manufacturer needs at least 60 points, plus the minimum score for quality systems and for finances. |
| 3. Site visit | Experts visit the site to confirm the information provided. Scores are confirmed or adjusted. A confirmed score of at least 70 points is needed to go forward. |
| 4. Agreement | A meeting with the manufacturer’s board to agree the work plan, the team, the manufacturer’s contribution and the targets for the product, recorded in a Technical Assistance Accord. |
How full applications are scored
| Area | Points | What we look at |
| Facility and utilities | 15 | Cleanrooms, air handling, purified water and backup power. Scored on what is in place, plus a funded plan to close any gaps. |
| Quality systems and data integrity | 20 (minimum 10) | A working quality system for deviations, CAPA and change control; validation; controls that protect the integrity of data. |
| Laboratory and stability testing | 10 | Quality control laboratories, testing equipment, and stability chambers suited to Nigeria’s climate (Zone IVb). |
| Product and dossier readiness | 15 | The product is on a WHO invitation; the active ingredient comes from a quality-assured source; how far the dossier has progressed; local excipients used where suitable. |
| Finances and co-financing | 10 (minimum 5) | The financial trend over three years and the ability to fund the manufacturer’s share. A loss year caused by exchange-rate movements does not on its own count against a manufacturer. |
| WHO prequalification team and governance | 10 | A named team reporting to the board, staff stability, commitment to training, and the capacity to close the gaps found. |
| Market access | 10 | Demand in Nigeria and other African markets, registrations held or planned, interest from buyers, and a commercial plan. Evidence counts for more than forecasts. |
| Jobs, local value and replacing imports | 10 | Jobs created or sustained, skills transfer, use of local inputs, how far the product is now imported, and whether it is on PVAC’s priority list. |
| Total | 100 |
7. Confidentiality?
Information you provide, and the findings of any assessment, are used only to plan and deliver technical assistance to your company. Assessments are carried out only by the MAPS consultants, EPRD and Lucid Haven, under a non-disclosure agreement. NAFDAC and other regulators are not part of the assessment teams. Your assessment report belongs to your company and is not shared with any other party, including regulators, without your written consent. MAPS reports only combined, anonymised results.
If an assessor finds a serious and immediate risk to patients, they will raise it with your company first, so that you can act and meet your own reporting obligations. MAPS will inform NAFDAC only if the risk is not addressed.
Once a Technical Assistance Accord is signed, a manufacturer may choose to seek NAFDAC’s advice, for example before submitting its dossier. This is entirely at the manufacturer’s discretion.
8. How to apply
Applications must be submitted through the MAPS Pillar 2 online application portal.
Applicants are required to:
- Complete the online Expression of Interest (EOI) form;
- Upload, within the same form, the five supporting documents listed in Section 4 of this Call.
All applications must be submitted no later than Tuesday, 17 November 2026, 17:00 WAT.
Questions regarding the Call, eligibility requirements, or the application process should be sent to:
- info@pvac.gov.ng
- steven.adeboye@lucidhaven.com
- services@lucidhaven.com
Alternatively, applicants may contact Dr Steven Adeboye at 0803 560 3817.
Questions received by Friday, 13 November 2026 will be answered, and responses shared with all applicants where relevant.
Registration has ended
9. Timeline
| Stage | Date |
| Call opens | Wednesday November 4, 2026 |
| Information session | Tuesday, 10 November 2026, 11:00 WAT (online) |
| Last date for questions | Friday, 13 November 2026 |
| EOI closing date | Tuesday November 17, 2026, 17:00 WAT |
| Shortlisted manufacturers informed | 18–19 November 2026 |
| Full applications due | Thursday, 26 November 2026 |
| Site visits | 30 November – 12 December 2026 |
| Technical Assistance Accords signed | on the last day of each site visit (between 30 November and 12 December 2026) |
10. Important notes
- Sending an EOI does not guarantee selection. All applicants will be told the outcome.
- MAPS may ask applicants to clarify information or provide further documents at any stage.
- Applicants bear their own costs of applying.
- The full selection criteria and scoring rules are set out in the MAPS Pillar 2 selection framework, which is available on request.
Annex 1: Eligible products
These products are on current WHO prequalification invitations and can be made by finished-product manufacturers. Other products on the same invitations are also eligible; the full lists are on the WHO Prequalification website (extranet.who.int/prequal). The facility notes show where a product needs a sterile area or a dedicated or contained area.
| Product and strength | Dosage form | ||
| Malaria (WHO 24th invitation, 19 November 2025) | |||
| Artemether/lumefantrine 20/120 mg and 80/480 mg; 20/120 mg dispersible | Tablet, dispersible tablet | ||
| Artesunate/amodiaquine 50/135 mg and 100/270 mg; 25/67.5 mg dispersible | Tablet, dispersible tablet | ||
| Sulfadoxine/pyrimethamine 500/25 mg; 250/12.5 mg dispersible (chemoprevention) | Tablet, dispersible tablet | ||
| Amodiaquine + sulfadoxine/pyrimethamine, co-blistered (seasonal malaria chemoprevention) | Dispersible tablets, co-blister | ||
| Artesunate 60 mg and 120 mg (severe malaria) | Powder for injection | ||
| Artesunate 50, 100 and 200 mg (rectal) | Suppository | ||
| Primaquine 7.5 mg and 15 mg | Tablet | ||
| Reproductive and maternal health (WHO 10th invitation, current version) | |||
| Oxytocin 10 IU/1 mL | Injection | ||
| Magnesium sulphate 500 mg/mL, 2 mL and 10 mL | Injection | ||
| Tranexamic acid 100 mg/mL, 5 mL and 10 mL | Injection | ||
| Misoprostol 200 micrograms | Tablet | ||
| Levonorgestrel 1.5 mg; ethinylestradiol + levonorgestrel 30 + 150 micrograms | Tablet | ||
| Medroxyprogesterone acetate 150 mg/mL | Injection | ||
| Benzathine benzylpenicillin 1.2 and 2.4 million units | Powder for injection | ||
| Child health (WHO invitations of 4 March 2025 and 23 January 2025) | |||
| Amoxicillin 125 mg and 250 mg | Dispersible tablet | ||
| Azithromycin 100 mg (or 50 mg) | Dispersible tablet | ||
| Zinc (sulfate or gluconate) 5 mg | Dispersible tablet, oral liquid | ||
| Tuberculosis (WHO 22nd and 23rd invitations, 24 February 2026) | |||
| Isoniazid 300 mg; 100 mg dispersible | Tablet, dispersible tablet | ||
| Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg; rifampicin/isoniazid 150/75 mg | Film-coated tablet | ||
| Rifampicin/isoniazid/pyrazinamide 75/50/150 mg (children) | Dispersible tablet | ||
| Pyridoxine (vitamin B6) | Tablet | ||
| HIV (WHO 23rd invitation, 9 July 2025) | |||
| Lamivudine/tenofovir disoproxil fumarate/dolutegravir (TLD) 300/300/50 mg | Tablet | ||
| Dolutegravir 10 mg; lamivudine/abacavir 60/120 mg (children) | Dispersible tablet | ||
| Sulfamethoxazole/trimethoprim/isoniazid/pyridoxine 800/160/300/25 mg | Scored tablet | ||
| Sickle cell disease (WHO 1st invitation, 24 July 2026) | |||
| Hydroxyurea 500 mg; 100 mg and 500 mg dispersible | Capsule, dispersible tablet | ||
| Neglected tropical diseases (WHO 9th invitation, 29 October 2024) | |||
| Albendazole 400 mg; mebendazole 500 mg | Chewable tablet | ||
| Praziquantel 600 mg | Scored tablet | ||
| Ivermectin 3 mg | Tablet | ||
| Azithromycin 500 mg | Tablet | ||
| Neonatal health (WHO Oct 3, 2024) | |||
| caffeine citrate | injection 20 mg/mL (10 mg base/mL) and oral liquid 20 mg/mL (10 mg base/mL | ||
Source: WHO Prequalification Unit, current invitations to manufacturers to submit an expression of interest, checked 23 October 2026. WHO revises these invitations from time to time; the version on the WHO website applies.